Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer.

IF 3.8 2区医学 Q2 ONCOLOGY Current Treatment Options in Oncology Pub Date : 2025-01-22 DOI:10.1007/s11864-025-01292-x

Yili Shen, Zhicong Liu, Yi Chen, Xuefei Shi, Shunli Dong, Bin Wang

{"title":"Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer.","authors":"Yili Shen, Zhicong Liu, Yi Chen, Xuefei Shi, Shunli Dong, Bin Wang","doi":"10.1007/s11864-025-01292-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Opinion statement: </strong>Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-025-01292-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Opinion statement: Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

小细胞肺癌免疫治疗应答的候选生物标志物。

观点声明：小细胞肺癌约占肺癌的15%，预后极差。免疫治疗与铂基化疗的结合提供了持续的总体生存益处，并成为广泛期小细胞肺癌一线治疗的标准。然而，只有少数患者获得了长期的益处。尽管目前正在研究新的免疫调节剂和联合策略，但迫切需要确定可能从这种治疗方法中获得临床益处的患者。对免疫疗法的适度治疗反应可以用多种机制来解释。传统的生物标志物不能指导小细胞肺癌的免疫治疗决策。值得注意的是，基于多组学数据的小细胞肺癌分子分型的最新进展可能会带来新的视野。本文综述了基于临床试验和临床前研究的小细胞肺癌免疫治疗的潜在生物标志物。此外，确定小细胞肺癌治疗的生物标志物的重要限制进行了讨论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.